Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Vitamin D deficiency, given its immunomodulatory role (including effects on regulatory T cells), has likewise been linked to greater ADA risk in rituximab-treated patients (32).

Source: Patient-related factors. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Narrative review.

Narrative review

Discusses existing research; systematic-review methods have not been established by this classification.

Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review

Source: Article title.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review

Narrative review · Frontiers in Immunology · 2026

Original publication title

Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review

Marco Allinovi; Jacopo Lomi; Matteo Accinno; Maxime Teisseyre; Michael Diomaiuti; Raffaele Madeo; Federica Allegretta; Andrea Matucci; Alessandra Vultaggio

Copyright © 2026 Allinovi, Lomi, Accinno, Teisseyre, Diomaiuti, Madeo, Allegretta, Matucci and Vultaggio.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Rituximab is a chimeric anti-CD20 monoclonal antibody widely used in immune-mediated and hematologic diseases, but its efficacy may be limited by the development of anti-rituximab antibodies (ADAs). This narrative review summarizes current evidence on the incidence, detection, and clinical implications of ADAs in nephropathies and other immune-mediated disorders. ADA prevalence varies markedly across diseases and is influenced by assay methodology, timing of testing, and patient immune background. Although not all ADAs are clinically relevant, their presence has been associated with lower rituximab levels, earlier B-cell repopulation, reduced clinical/immunological remission, more frequent relapses, and hypersensitivity reactions.

Overall, ADAs represent an underrecognized factor that may affect rituximab efficacy and safety, supporting the need for improved monitoring and more personalized therapeutic strategies.

Authors’ abstract

Rituximab is a chimeric anti-CD20 monoclonal antibody widely used in immune-mediated and hematologic diseases, but its efficacy may be limited by the development of anti-rituximab antibodies (ADAs). This narrative review summarizes current evidence on the incidence, detection, and clinical implications of ADAs in nephropathies and other immune-mediated disorders. ADA prevalence varies markedly across diseases and is influenced by assay methodology, timing of testing, and patient immune background. Although not all ADAs are clinically relevant, their presence has been associated with lower rituximab levels, earlier B-cell repopulation, reduced clinical/immunological remission, more frequent relapses, and hypersensitivity reactions.

Overall, ADAs represent an underrecognized factor that may affect rituximab efficacy and safety, supporting the need for improved monitoring and more personalized therapeutic strategies.

Publication and source details

Original title: Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review

Marco Allinovi; Jacopo Lomi; Matteo Accinno; Maxime Teisseyre; Michael Diomaiuti; Raffaele Madeo; Federica Allegretta; Andrea Matucci; Alessandra Vultaggio

Frontiers in Immunology · 2026

* Correspondence: Marco Allinovi, marco.allinovi@gmail.comCopyright © 2026 Allinovi, Lomi, Accinno, Teisseyre, Diomaiuti, Madeo, Allegretta, Matucci and Vultaggio.2026Allinovi, Lomi, Accinno, Teisseyre, Diomaiuti, Madeo, Allegretta, Matucci and Vultaggiohttps://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.The author(s) declared that financial support was not received for this work and/or its publication.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T21:40:44.076429+00:00

DOI: 10.3389/fimmu.2026.1896560 · PMC13620468